{"id":"https://genegraph.clinicalgenome.org/r/20189022-424d-42ad-a037-456941e579e5v1.0","type":"EvidenceStrengthAssertion","dc:description":"The *ELP4* gene was first reported in relation to aniridia in 2013, with the publication of an affected individual harboring a *de novo* variant within a highly conserved region of intron 9 (PMID: 24290376). Subsequent publications have established that affected individuals may be diagnosed between early childhood and adulthood, and present with bilateral aniridia and in some cases with cataracts (PMID: 17679951, PMID: 22991255, PMID: 26010655). Patients may exhibit foveal hypoplasia, nystagmus, and/or glaucoma as well. Per criteria outlined by the ClinGen Lumping & Splitting Working Group, the molecular mechanism (monoallelic disruption of intronic cis elements that are known to regulate expression of the adjacent *PAX6* gene) was found to be consistent among the published cases. In addition, the phenotypes appeared to match those of patients with dominant variants in the *PAX6* locus itself resulting in aniridia and other forms of eye disease. Therefore, cases of eye disease caused by inherited variants disrupting cis elements located in the *ELP4* locus have been curated under a single disease entity referred to as ocular dysgenesis caused by defects in *PAX6* regulation.\n\nFive suspected disease-causing variants have been scored as part of this curation (one single nucleotide substitution in intron 9 and four larger deletion variants encompassing the 3â€™ intronic regions as well as other coding regions of *ELP4*. These variants have been collectively reported in five probands in four publications (PMID: 24290376, PMID: 17679951, PMID: 22991255, PMID: 26010655). All five probands were heterozygous for their respective variants. While the literature also includes similar cases harboring additional deletion variants encompassing not only intronic elements from *ELP4* but also regions of adjacent loci such as *PAX6* (PMID: 11087823, ), this curation has focused only on the monogenic cases limited to the *ELP4* locus alone. The mechanism of pathogenicity appears to be monoallelic disruption of enhancer elements located in the introns of *ELP4* but required for efficient *PAX6* transactivation during ocular development through a feed forward mechanism mediated by binding of the PAX6 transcription factor itself (PMID: 24290376). Although co-segregation of the phenotype with the presence of the variant has been observed in at least 2 published families, the family sizes were not sufficient to contribute to the scoring of the gene-disease relationship (PMID: 17679951). Please note that loss-of-function variants within the coding regions of *ELP4* are not expected to contribute to eye disease, but may contribute to a separate condition with neurodevelopmental phenotypes and an autosomal recessive mode of inheritance (PMID: 35698786).\n\nThis gene-disease association is also supported by biochemical evidence indicating that cis-regulatory elements within the *ELP4* introns 7, 8, and 9 function as long-range enhancer elements, essential for normal expression of *PAX6* during ocular development (PMID: 17014839, PMID: 24290376). Chromatin immunoprecipitation studies confirm that the PAX6 protein binds to a conserved 800-bp cis element known as SIMO in intron 9 of *ELP4* (PMID: 31700164), identifying this sequence as an autoregulatory PAX6 binding site mediating a positive feedback loop. Studies from mice and zebrafish have shown that the SIMO element from *ELP4* drives transgenic reporter expression within lens tissue (PMID: 24290376). Mice with a heterozygous deletion encompassing *Pax6*, *Elp4*, and other nearby genes have small eyes as well as other phenotypes such as a white belly. Interestingly, the introduction of a transgene containing *Pax6* and part of *Elp4* including the SIMO region is sufficient to rescue the aniridia, indicating that the rest of *Elp4* is dispensable for the ocular phenotype (PMID: 11889558).\n\nIn summary, *ELP4* has moderate evidence of association with ocular dysgenesis caused by defects in *PAX6* regulation. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a Moderate classification. Additional genetic evidence from cases with variants limited to the *ELP4* locus and confirmed disruption of *PAX6* expression will be required to reach a more definitive classification. This classification was approved by the ClinGen Glaucoma and Neuro-Ophthalmology Gene Curation Expert Panel on November 16th, 2023 (SOP Version 10).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/20189022-424d-42ad-a037-456941e579e5","GCISnapshot":"https://genegraph.clinicalgenome.org/r/095db206-85a6-491a-929c-bb4db8d1240a","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/095db206-85a6-491a-929c-bb4db8d1240a_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2023-11-16T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/095db206-85a6-491a-929c-bb4db8d1240a_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2024-06-28T18:21:01.016Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/095db206-85a6-491a-929c-bb4db8d1240a_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/095db206-85a6-491a-929c-bb4db8d1240a_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/252b892c-a78c-4cbf-8f6a-14c2651da26b","type":"EvidenceLine","dc:description":"Scoring has not been recommended as the experiment is consistent with an important contribution of *Pax6* and cis elements in the *Elp4* locus to the formation of the iris, but argues against a role of the Elp4 protein in the disease.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec9cf6cb-5e9f-40f2-85ff-e78190af657c","type":"Finding","dc:description":"This is a naturally occurring mouse model with aniridia and other phenotypes due to a heterozygous deletion of 11 genes that has been previously described in PMID: 9192846. Crossing this mouse model to introduce a transgene to restore Pax6 and the 3' end of the Elp4 locus (including the Pax6 regulatory regions but omitting the first three exons) rescued the aniridia phenotype (Figure 4). This indicates that haploinsufficiency for the Elp4 gene product is likely unrelated to the mechanism underlying the aniridia phenotype.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11889558","rdfs:label":"Aniridia in the Sey1H mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/4c788f04-e14a-4be1-b911-9cb6c48f5fe0","type":"EvidenceLine","dc:description":"This indicates that the 3' end of the Elp4 gene product in combination is sufficient to rescue the aniridia phenotype of the model, while a functional Elp4 gene product is likely unrelated to the mechanism underlying the aniridia phenotype.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a7629f0e-7d22-4db0-b782-d65c2d827d3e","type":"Finding","dc:description":"This is a naturally occurring mouse model with aniridia and other phenotypes due to a heterozygous deletion of 11 genes that has been previously described in PMID: 9192846. Crossing this mouse model to introduce a transgene to restore Pax6 and the 3' end of the Elp4 locus (including the Pax6 regulatory regions but omitting the first three exons) rescued the aniridia phenotype (Figure 4). This indicates that haploinsufficiency for the Elp4 gene product is likely unrelated to the mechanism underlying the aniridia phenotype.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11889558","rdfs:label":"Rescue of the Sey1H mouse with a Pax6 transgene","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/095db206-85a6-491a-929c-bb4db8d1240a_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8650a5e6-4c41-41a9-bb7d-d97c4d47ed9e","type":"EvidenceLine","dc:description":"The data convincingly argue for the role of the SIMO cis element in driving disease-relevant gene expression. However, it is not clear whether this is equivalent to supporting the role of ELP4 in disease.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/86e75c25-8f9f-478c-9614-72f63eeee35e","type":"Finding","dc:description":"The SIMO cis element from ELP4 drives LacZ expression in the transgene context within early surface ectoderm, lens, diencephalon, and rhombencephalon of mouse embyros (Figures 2A, 2B, S2). Later, expression is present in lens epithelium and neuroretina (Figure 2C). This evidence is consistent with its suspected role in promoting the expression of PAX6, which is similarly associated with Aniridia through a dominant mode of inheritance.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24290376","rdfs:label":"The SIMO element from ELP4 drives lens expression of LacZ.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/76252cad-b79e-4adf-9878-6c4c14ead48f","type":"EvidenceLine","dc:description":"The data convincingly argue for the role of the ELP4 cis elements in driving disease-relevant gene expression. Additional scoring has been considered due to the inclusion of a control deleting the DRR portion specifically.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f5d9822b-22c2-4272-9571-ea4f28c8f846","type":"Finding","dc:description":"Deletion of the DRR elements triggers loss of reporter gene expression, revealing the mechanism by which the loss of PAX6 can be accomplished by variants outside the coding sequencing.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17014839","rdfs:label":"The PAX6 DRR (located in ELP4) drives ocular expression.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.75},{"id":"https://genegraph.clinicalgenome.org/r/591dae2d-19f8-455c-8a19-01883c70099a","type":"EvidenceLine","dc:description":"This scoring is considered appropriate given the definitive relationship between the PAX6 gene and aniridia / the broader disease entity of ocular dysgenesis.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/66a70072-3701-43af-a6c9-511fe8ad266e","type":"Finding","dc:description":"Intron 7, intron 8, and particularly intron 9 of ELP4 contain cis motifs that promote the expression of PAX6, which is definitively associated with ocular dysgenesis, including cases of aniridia. PAX6 associates with these cis motifs, as shown by immunoprecipitation of PAX6 from the chromatin fraction (PMID: 31700164).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31700164","rdfs:label":"Cis motifs in the ELP4 locus control the expression of PAX6.","demonstrates":{"id":"obo:MI_0935"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/dd7922e9-d6b1-4f7c-91ad-8911002ef6ec","type":"EvidenceLine","dc:description":"High expression of ELP4 in the ocular tissues is consistent with a role in the development of the iris, despite its ubiquitous expression. On the other hand, scoring has not been recommended as the mechanism of disease is independent on the ELP4 mRNA.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f280714a-122e-42ec-94e0-9f0aec589e79","type":"Finding","dc:description":"Profiling of ELP4 mRNA expression across various human tissues found that corneal endothelium, lens, and retina express the highest levels of ELP4, although the gene is ubiquitously expressed (PMID: 30239781). A second database that did not include ocular samples found high expression in the cerebellum as well (PMID: 23715323).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30239781","rdfs:label":"ELP4 is normally expressed in corneal endothelium.","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.75}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2.25},{"id":"https://genegraph.clinicalgenome.org/r/095db206-85a6-491a-929c-bb4db8d1240a_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/095db206-85a6-491a-929c-bb4db8d1240a_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f9bf4f60-db32-414d-b112-e64a4b4e53f1_proband_segregation","type":"FamilyCosegregation","dc:description":"The family meets the minimum number of segregations required for calculation of the estimated LOD score and inclusion in genetic evidence.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17679951","rdfs:label":"D'Elia_2007_Family_A16","estimatedLodScore":1.51,"family":{"id":"https://genegraph.clinicalgenome.org/r/f9bf4f60-db32-414d-b112-e64a4b4e53f1","type":"Family","rdfs:label":"D'Elia_2007_Family_A16","member":{"id":"https://genegraph.clinicalgenome.org/r/42ba9acd-3c0d-46b4-a8d3-f78a82f19b2b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17679951","rdfs:label":"D'Elia_2007_Family_A16_I:2","allele":{"id":"https://genegraph.clinicalgenome.org/r/1081753b-9c87-4be6-b3f1-3dce80713155","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"GRCh38 11p13(chr11:31742323-31754158)x1"},"detectionMethod":"The PAX6 gene was analyzed for point variants by SSCP and dHPLC. Copy number variation within the PAX6, WT1, and ELP4 loci was assessed by TaqMan-based quantitative real-time PCR.","firstTestingMethod":"SSCP","phenotypeFreeText":"Aniridia was bilateral, while cataract was observed only in one eye.","phenotypes":["obo:HP_0000518","obo:HP_0000526"],"previousTesting":true,"previousTestingDescription":"The PAX6 gene was analyzed for point variants by SSCP and dHPLC, while TaqMan-based quantitative real-time PCR was used to detect PAX6 and WT1 deletions / copy number variations.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/5ebbf94f-0e94-4dcd-b5ec-1098cb7645c0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17679951","allele":{"id":"https://genegraph.clinicalgenome.org/r/1081753b-9c87-4be6-b3f1-3dce80713155"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Aniridia was bilateral in all affected family members, while cataract was observed in some individuals but not others.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":6,"phenotypes":["obo:HP_0000518","obo:HP_0000526"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/42ba9acd-3c0d-46b4-a8d3-f78a82f19b2b"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/593a0335-eaf2-4d6c-b455-5ac51faea7cb","type":"EvidenceLine","dc:description":"This is an intron 9 variant that is suspected to impact PAX6 expression based on the disease mechanism but lacks experimental evidence of direct impact. Down-scoring has been performed since this is only the first example of a single nucleotide variant in intron 9 and does not closely match the established pattern of larger intronic deletion variants.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/593a0335-eaf2-4d6c-b455-5ac51faea7cb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24290376","allele":{"id":"https://genegraph.clinicalgenome.org/r/ff447fb4-265d-46a8-a4ac-577e4c1968df","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_019040.5(ELP4):c.1143+14176C>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA267692"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/876b5106-5ace-4cea-b43d-b33d0f66e5ee","type":"EvidenceLine","dc:description":"The variant has been up-scored to reflect its compatibility with the known mechanism of disease by which loss of critical sequences in ELP4 intron 9 decrease PAX6 expression to disease-causing levels. Down-scoring has been performed due to the absence of functional evidence confirming loss of PAX6 expression as well as genotyping methods limiting the determination of the exact breakpoints of the deletion.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/876b5106-5ace-4cea-b43d-b33d0f66e5ee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17679951","allele":{"id":"https://genegraph.clinicalgenome.org/r/1081753b-9c87-4be6-b3f1-3dce80713155"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/e52b861a-b89a-4007-90bc-56d09fd76be0","type":"EvidenceLine","dc:description":"The variant has been up-scored for its compatibility with the known mechanism of disease, in which deletions of a critical cis element in intron 9 of the ELP4 locus causes loss of PAX6 expression. Down-scoring has been performed for the lack of functional data confirming the effect on PAX6 expression and for the genotyping limitations.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e52b861a-b89a-4007-90bc-56d09fd76be0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26010655","allele":{"id":"https://genegraph.clinicalgenome.org/r/6d1167c3-f3f3-4722-93d7-4e3b6f435034","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"GRCh37 11p13(chr11:31616315-31671774)x1"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5ebbf94f-0e94-4dcd-b5ec-1098cb7645c0","type":"EvidenceLine","dc:description":"The variant has been up-scored to reflect its compatibility with the known mechanism of disease by which loss of critical sequences in ELP4 intron 9 decrease PAX6 expression to disease-causing levels. Down-scoring has been performed due to the absence of functional evidence confirming loss of PAX6 expression as well as genotyping methods limiting the determination of the exact breakpoints of the deletion.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5ebbf94f-0e94-4dcd-b5ec-1098cb7645c0_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/380930f5-53fd-425f-8d90-fb87fb52536a","type":"EvidenceLine","dc:description":"The variant has been up-scored for its suspected de novo state and for compatibility with the known mechanism of disease, in which variants that delete critical cis regulatory elements in intron 9 of the ELP4 locus result in decreased expression of PAX6. Down-scoring has been performed for lack of confirmation of functional impact on PAX6 expression and for the limitations of the genotyping method.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/380930f5-53fd-425f-8d90-fb87fb52536a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22991255","allele":{"id":"https://genegraph.clinicalgenome.org/r/1081753b-9c87-4be6-b3f1-3dce80713155"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":4.75}],"evidenceStrength":"Moderate","sequence":8539,"specifiedBy":"GeneValidityCriteria10","strengthScore":7,"subject":{"id":"https://genegraph.clinicalgenome.org/r/h-Awud5Wkcw","type":"GeneValidityProposition","disease":"obo:MONDO_0700246","gene":"hgnc:1171","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_095db206-85a6-491a-929c-bb4db8d1240a-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}